141 related articles for article (PubMed ID: 25661917)
1. [Mycophenolate mofetil--20 years of experience in treatment of rheumatic diseases].
Walkiewicz-Pielaszek K; Swacha M; Bułło-Piontecka B; Rutkowski B; Olesiñska M
Postepy Hig Med Dosw (Online); 2015 Feb; 69():176-87. PubMed ID: 25661917
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil: a dermatologic perspective.
Mydlarski PR
Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
[TBL] [Abstract][Full Text] [Related]
3. [Mycophenolate mofetil in the treatment of selected connective tissue diseases].
Batko B; Krawiec P; Osieleniec J; Sułowicz W
Przegl Lek; 2013; 70(9):724-9. PubMed ID: 24455833
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?
Iaccarino L; Rampudda M; Canova M; Della Libera S; Sarzi-Puttinic P; Doria A
Autoimmun Rev; 2007 Jan; 6(3):190-5. PubMed ID: 17289556
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology.
Broen JCA; van Laar JM
Nat Rev Rheumatol; 2020 Mar; 16(3):167-178. PubMed ID: 32055040
[TBL] [Abstract][Full Text] [Related]
7. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
Allison AC; Eugui EM
Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in multiple sclerosis.
Frohman EM; Brannon K; Racke MK; Hawker K
Clin Neuropharmacol; 2004; 27(2):80-3. PubMed ID: 15252268
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G
Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
Larkin G; Lightman S
Ophthalmology; 1999 Feb; 106(2):370-4. PubMed ID: 9951492
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis.
González-Rivera TC; McCune J
Immunotherapy; 2011 Dec; 3(12):1431-40. PubMed ID: 22091679
[TBL] [Abstract][Full Text] [Related]
12. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
Behrend M
Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
[TBL] [Abstract][Full Text] [Related]
13. Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis.
Nieto E; Escudero E; Navarro E; Yáñez-Mo M; Martín A; Pérez de Lema G; Sánchez-Madrid F; Mampaso F
J Am Soc Nephrol; 2002 Apr; 13(4):937-945. PubMed ID: 11912253
[TBL] [Abstract][Full Text] [Related]
14. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
[TBL] [Abstract][Full Text] [Related]
15. From mechanisms to long-term benefits.
Mamelok R
Transplantation; 2005 Feb; 79(3 Suppl):S43-4. PubMed ID: 15699749
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.
Siepmann K; Huber M; Stübiger N; Deuter C; Zierhut M
Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):788-94. PubMed ID: 16163494
[TBL] [Abstract][Full Text] [Related]
17. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
19. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.
Lenz O; Fornoni A; Contreras G
Drugs; 2005; 65(17):2429-36. PubMed ID: 16296869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
